Allergan adopts poison pill in face of Valeant bid
April 23, 2014 at 03:48 AM EDT
The Botox maker’s shareholder rights plan effectively blocks activist investor Bill Ackman, who has teamed with Valeant on the hostile advance, from growing his holding.
